Clin2
NCT05912621Possibly a fitRecruiting

Tirzepatide for fat-related body dysfunction in overweight adults

ObesityOverweight and ObesityOverweight

Treatments studied

Part of Hormones & metabolism clinical trials.

This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
66 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You don’t have diabetes: your fasting glucose must be under 126 mg/dL while not taking any glucose-lowering medications
  • You are 18 to 70 years old and have a BMI between 27 and 39.9
  • If your BMI is 27–29.9, you need at least one weight-related issue (like high blood pressure, abnormal cholesterol/triglycerides, or prediabetes-related conditions)
  • You have not had bariatric (weight loss) surgery or liposuction
  • Your weight has not changed by more than 2 kg in the last 6 weeks
  • You are not pregnant or breastfeeding, and you are not using weight-loss or glucose-raising medicines (including GLP-1 medicines) currently or within the last 3 months

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07099742Not yet recruiting
Tirzepatide for weight loss in adults with obesity

This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.

Comilla
NCT07247084Recruiting· Phase 4
Tirzepatide for weight loss in adults with obesity

This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.

Altrincham
NCT05933499Recruiting· Phase 2
Tirzepatide and bimagrumab for body fat and insulin sensitivity

This Phase 2 study tests two medicines to see how they change body fat, insulin sensitivity, and bone health in adults with obesity. It may help people who have tried lifestyle changes to lose weight but have not been able to, though diabetes and several health conditions must be ruled out first.

Boston, Massachusetts
NCT06439277Recruiting· Phase 3
Tirzepatide for teens with obesity and related health problems

This study tests a medication called tirzepatide (a once-weekly injection) to help teenagers with obesity and related health conditions lose weight. It aims to see if the drug is safe and effective for this age group.

Los Angeles, California
NCT07574723Recruiting
Tirzepatide dosing strategy to manage side effects in obesity

This study tests a new medication called tirzepatide, given at carefully adjusted doses, to help people with obesity lose weight while reducing unwanted side effects. Tirzepatide is a newer injectable medicine that helps control appetite and blood sugar.

Kuwait City
NCT06180616Not yet recruiting· Phase 2
Tirzepatide for type 1 diabetes with overweight or obesity

This trial tests if tirzepatide, a weekly injection, can help people with type 1 diabetes who are also overweight or obese. The goal is to see if it improves blood sugar control and supports weight loss.

Hear when a new Obesity trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.